Clinical Trial – Monitoring and Treatment of Relapsed Leukemia – Leukemia

  • 1

1 Answer

These messages are for mutual support and information sharing only. Always consult your doctor before trying anything you read here.
Prescient Therapeutics, Ltd. is running a clinical trial to test drugs called PTX-200 and Cytarabine to treat acute leukemia. A phase I-II open label study of PTX-200 in combination with cytarabine in the treatment of relapsed or refractory acute leukemia. The drugs are PTX-200 and Cytarabine.
Study Type : Interventional (Clinical Trial)
Estimated Enrollment : 40 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I-II Study of Triciribine Phosphate Monohydrate (PTX-200) Plus Cytarabine in Refractory or Relapsed Acute Leukemia
Actual Study Start Date : September 2016
Estimated Primary Completion Date : March 2018
Estimated Study Completion Date : September 2018
Contact: Mandeep Grewal
NCT Number
NCT number: NCT02930109
For enrollment please visit